Home
Resource
Structure-activity studies of novel noncamptothecin topoisomerase I-targeting agents
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(3.76 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Feng, Wei. Structure-activity studies of novel noncamptothecin topoisomerase I-targeting agents. Retrieved from https://doi.org/doi:10.7282/T3WD40TK

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleStructure-activity studies of novel noncamptothecin topoisomerase I-targeting agents
NameFeng, Wei (author); LaVoie, Edmond (chair); Rice, Joseph (internal member); Kimball, S. David (internal member); Jones, Roger (outside member); Rutgers University; Graduate School - New Brunswick
Date Created
Other Date2008-05 (degree)
SubjectMedicinal Chemistry, DNA topoisomerase I
Extentxiv, 219 p. : ill.
DescriptionTopoisomerases are ubiquitous enzymes that participate in processes such as DNA replication, transcription and repair. Two camptothecin derivatives, topotecan (Hycamtin®) and irinotican (CPT-11/ Camptosar®), are currently used in the clinic as topoisomerse I targeting anticancer agents. Camptothecins can stabilize the enzyme-DNA cleavage complex, leading to DNA damage and ultimately cell death. Despite their unique tumor suppression mechanism, topotecan and irinotican can undergo hydrolysis and inactivation in vivo due to an unstable lactone moiety. In addition, both topotecan and irinotican are substrates for efflux transporters, BCRP and MDR1, which are associated with drug resistance. 8,9-Dimethoxy-5-(2-dimethylaminoethyl)-2,3-methylenedioxy- 5H-dibenzo[c,h][1,6]naphthyridine-6- one (ARC-111) has been identified as exceptionally active TOP1-targeting agent with potent antitumor activity both in vitro and in vivo. Unlike camptothecins, ARC-111 is not a substrate for major efflux transporters, and does not bind to human serum albumin. ARC-111 structurally related analogs, 12-carboxamides of benzo[i]phenathridine and the "reversed lactams" have also exhibited excellent cytotoxicity and potent TOP1 targeting activity. In this dissertation, further insights into structure-activity relationship of ARC-111 and related compounds have been carefully examined. Alteration of both D-ring and side chain of ARC-111 have afforded potent TOP1-targeting agents. Inspired by the success of ARC-111, the design, synthesis and biological activities of other B-ring modified benzo[i]phenathridines have been systematically investigated. In review of possible metabolites of ARC-111, together with the known structure-activity relationships associated with the "reversed lactams", 11-carboxamides and 12-carboxamides of benzo[i]phenathridine, have prompted the examination of α,α-dimethyl substitution on the amino side chain on pharmacologic activity. Efficient synthetic methods associated with these novel non-camptothecin anticancer agents have also been developed. Several agents identified in this study have demonstrated excellent cancer cell cytotoxicity, TOP1 targeting specificity, as well as in vivo antitumor efficacy, comparable as the lead compound, ARC-111.
NotePh.D.
NoteIncludes bibliographical references (p. 198-218)
Noteby Wei Feng
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3WD40TK
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameNjNbRU
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024